-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, UroGen Pharma's UGN-102 Achieves 80.6% Probability Of Sustained Complete Response At 18 Months In Phase 3 ENVISION Trial

Benzinga·04/28/2025 05:40:07
Listen to the news
  • 18-month DOR of 80.6% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%)
  • Data unveiled during a Podium Presentation at the American Urological Association (AUA) 2025 Annual Meeting in Las Vegas, Nevada